Patents by Inventor Rik RADEMAKER

Rik RADEMAKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 12637515
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 26, 2026
    Assignee: GENMAB A/S
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van Den Brink, Dennis Verzijl
  • Humanized or chimeric CD3 antibodies
    Patent number: 12617854
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: May 5, 2026
    Assignee: GENMAB A/S
    Inventors: Rik Rademaker, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 12570751
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: March 10, 2026
    Assignees: Genmab A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz, Edward Van Den Brink, Dennis Verzijl
  • ANTIBODIES
    Publication number: 20250340647
    Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: November 6, 2025
    Inventors: Louise KOOPMAN, Patrick ENGELBERTS, Dennis VERZIJL, Edward N. VAN DEN BRINK, Rik RADEMAKER, Sieto BOSGRA, Frederikke L. EGEROD, David SATIJN, Esther C. W. BREIJ
  • Anti-DR5 antibodies and methods of use thereof
    Patent number: 12247080
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: March 11, 2025
    Assignee: GENMAB B.V.
    Inventors: Marije Overdijk, Kristin Strumane, Rik Rademaker, Esther Breij, Janine Schuurman, Paul Parren
  • ANTIBODIES
    Publication number: 20240392032
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 26, 2024
    Publication date: November 28, 2024
    Inventors: David SATIJN, Esther C.W. Breij, Bart E.C.G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • ANTIBODIES AGAINST PD-L1
    Publication number: 20240317861
    Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: December 14, 2023
    Publication date: September 26, 2024
    Inventors: Isil ALTINTAS, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rik RADEMAKER, Paul PARREN, Bart DE GOEIJ
  • Multispecific antibodies against CD40 and CD137
    Patent number: 12077596
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: September 3, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Antibodies
    Patent number: 11970544
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: April 30, 2024
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11939388
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: March 26, 2024
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230374131
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: February 14, 2023
    Publication date: November 23, 2023
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20230312693
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 5, 2023
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO, Jeffrey B STAVENHAGEN
  • BISPECIFIC ANTIBODIES BINDING TO 5T4 AND CD3 FOR USE IN TREATMENT OF CANCER
    Publication number: 20230257479
    Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Type: Application
    Filed: September 11, 2020
    Publication date: August 17, 2023
    Inventors: David SATIJN, Esther C.W. BREIJ, Bart E.C.G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN, Reshma Abdulla RANGWALA, Sri GHATTA, Ruud BRAKENHOFF, Rieneke VAN DE VEN
  • Humanized or chimeric CD3 antibodies
    Patent number: 11613575
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 28, 2023
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20230089969
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: August 3, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20230087745
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: August 24, 2022
    Publication date: March 23, 2023
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ, Edward VAN DEN BRINK, Dennis VERZIJL
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230027394
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Rik RADEMAKER, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11542323
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 3, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B Stavenhagen
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11524995
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 13, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergström, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B. Stavenhagen
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220389101
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 8, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN